Tilgen W - Search Results

1

Chemosensitivity testing in malignant melanoma.

Ugurel S, Tilgen W, Reinhold U. Ugurel S, et al. Among authors: tilgen w. Recent Results Cancer Res. 2003;161:81-92. doi: 10.1007/978-3-642-19022-3_8. Recent Results Cancer Res. 2003. PMID: 12528801

2

Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study.

Pföhler C, Cree IA, Ugurel S, Kuwert C, Haass N, Neuber K, Hengge U, Corrie PG, Zutt M, Tilgen W, Reinhold U. Pföhler C, et al. Among authors: tilgen w. Anticancer Drugs. 2003 Jun;14(5):337-40. doi: 10.1097/00001813-200306000-00002. Anticancer Drugs. 2003. PMID: 12782938 Clinical Trial.

3

In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.

Ugurel S, Schadendorf D, Pföhler C, Neuber K, Thoelke A, Ulrich J, Hauschild A, Spieth K, Kaatz M, Rittgen W, Delorme S, Tilgen W, Reinhold U; Dermatologic Cooperative Oncology Group. Ugurel S, et al. Among authors: tilgen w. Clin Cancer Res. 2006 Sep 15;12(18):5454-63. doi: 10.1158/1078-0432.CCR-05-2763. Clin Cancer Res. 2006. PMID: 17000680 Clinical Trial.

4

Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with bcl-2 and bcl-x expression and is sensitive to modulation by interferon-gamma.

Ugurel S, Seiter S, Rappl G, Stark A, Tilgen W, Reinhold U. Ugurel S, et al. Among authors: tilgen w. Int J Cancer. 1999 Aug 27;82(5):727-36. doi: 10.1002/(sici)1097-0215(19990827)82:5<727::aid-ijc17>3.0.co;2-e. Int J Cancer. 1999. PMID: 10417772

5

Antitumoral action of 2-deoxy-D-glucose tetraacetate in human melanoma cells.

Reinhold U, Ugurel S, Tilgen W, Kadiata MM, Olivares E, Nadi AB, Malaisse WJ. Reinhold U, et al. Among authors: tilgen w. Oncol Rep. 2000 Sep-Oct;7(5):1093-7. doi: 10.3892/or.7.5.1093. Oncol Rep. 2000. PMID: 10948345

6

Facts and pitfalls in the detection of tyrosinase mRNA in the blood of melanoma patients by RT-PCR.

Seiter S, Rappl G, Tilgen W, Ugurel S, Reinhold U. Seiter S, et al. Among authors: tilgen w. Recent Results Cancer Res. 2001;158:105-12. doi: 10.1007/978-3-642-59537-0_10. Recent Results Cancer Res. 2001. PMID: 11092037

7

Detection of tumor-associated circulating mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma.

Hasselmann DO, Rappl G, Rössler M, Ugurel S, Tilgen W, Reinhold U. Hasselmann DO, et al. Among authors: tilgen w. Oncol Rep. 2001 Jan-Feb;8(1):115-8. doi: 10.3892/or.8.1.115. Oncol Rep. 2001. PMID: 11115581

8

Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival.

Ugurel S, Rappl G, Tilgen W, Reinhold U. Ugurel S, et al. Among authors: tilgen w. J Clin Oncol. 2001 Jan 15;19(2):577-83. doi: 10.1200/JCO.2001.19.2.577. J Clin Oncol. 2001. PMID: 11208853

9

Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy.

Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U. Ugurel S, et al. Among authors: tilgen w. Cancer. 2001 Jul 15;92(2):369-76. doi: 10.1002/1097-0142(20010715)92:2<369::aid-cncr1332>3.0.co;2-u. Cancer. 2001. PMID: 11466692

10

Detection of tumor-associated circulating mRNA in patients with disseminated malignant melanoma.

Rappl G, Hasselmann DO, Rössler M, Ugurel S, Tilgen W, Reinhold U. Rappl G, et al. Among authors: tilgen w. Ann N Y Acad Sci. 2001 Sep;945:189-91. Ann N Y Acad Sci. 2001. PMID: 11708477

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

245 results

Search Page

Filters